Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 4:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 342 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Phase 3 Interventional Results available

Double Cord Versus Haploidentical (BMT CTN 1101)

NCT01597778
Conditions
Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, Burkitt's Lymphoma, Follicular Lymphoma, Hodgkin Lymphoma, Mantle Cell Lymphoma, Non-Hodgkin Lymphoma
Interventions
Haploidentical Bone Marrow Transplant, Double Umbilical Cord Blood Transplant
Biological
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 70 Years
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
39
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 32 more
Conditions
Refractory Plasma Cell Myeloma
Interventions
Bortezomib, Lenalidomide, Dexamethasone
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
19 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Multiple Myeloma
Interventions
PCV 13
Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Non Hodgkin Lymphoma, Follicular Lymphoma, Indolent Lymphoma, B-cell Lymphoma, Transformed Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma
Interventions
Zydelig
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
3
States / cities
Miami, Florida • Baltimore, Maryland • Milwaukee, Wisconsin
Conditions
Multiple Myeloma
Interventions
CT-011, Dendritic Cell Fusion Vaccine
Drug · Biological
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Best Available Therapy (BAT)
Procedure · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
22
States / cities
Palo Alto, California • Aurora, Colorado • Evanston, Illinois + 17 more
Conditions
Degenerative Spondylolisthesis or Retrolisthesis, Spinal Stenosis, Stenosing Lesion.
Interventions
Posterior Pedicle Screw System
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
20 Years to 80 Years
Enrollment
399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
26
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 23 more
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
carmustine, cisplatin, cyclophosphamide, dexamethasone, etoposide, gemcitabine hydrochloride, melphalan, paclitaxel, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Drug · Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 2 Interventional Results available

Tandem Auto-Allo Transplant for Lymphoma

NCT01181271
Conditions
Diffuse, Large B-Cell, Lymphoma, Lymphoma, Low-Grade, T-Cell Lymphoma, Mantle-Cell Lymphoma, Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic
Interventions
Busulfan (conditioning for AUTO transplant), Etoposide (conditioning for AUTO transplant), Cyclophosphamide (conditioning for AUTO transplant), Mesna (prior to AUTO transplant), autologous (auto) peripheral blood stem cell transplantation, Neupogen, Fludarabine (conditioning for ALLO Transplant), Busulfan (conditioning for ALLO Transplant), non-myeloablative allogeneic (allo) transplant, Tacrolimus, Sirolimus, Methotrexate
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
Interventions
Bendamustine, Carmustine, Etoposide, Melphalan, Cytarabine, Alemtuzumab, Autologous Stem Cell Transplantation, Allogeneic Stem Cell Transplantation, Rituximab
Drug · Biological
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
New York, New York
Conditions
Autologous Stem Cell Transplantation
Interventions
G-CSF plus plerixafor
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 78 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
8
States / cities
Duarte, California • Tampa, Florida • Atlanta, Georgia + 5 more
Conditions
Degenerative Spondylolisthesis, Lumbar Spinal Stenosis
Interventions
LimiFlex, Fusion Instrumentation, Decompression, Fusion
Device · Procedure
Lead sponsor
Empirical Spine, Inc.
Industry
Eligibility
25 Years to 80 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
28
States / cities
Tempe, Arizona • Oakland, California • Redwood City, California + 24 more
Terminated Not applicable Interventional Results available

Comparison of Skin Substitutes Used in Burn Care

NCT00676013
Conditions
Burns
Interventions
Integra, AlloDerm, Homograft, Autograft
Procedure
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
Up to 90 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2011
U.S. locations
2
States / cities
Galveston, Texas
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

rhBMP-2 Versus Vivigen in Lumbar Fusion Procedures

NCT03527966
Conditions
Lumbar Spine Degeneration
Interventions
5cc Vivigen and local autograft, Small kit rhBMP-2 with local autograft
Biological
Lead sponsor
Virtua Health, Inc.
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Mount Holly, New Jersey
Conditions
Burns
Interventions
ReCell® Autologous Cell Harvesting Device
Device
Lead sponsor
Avita Medical
Industry
Eligibility
5 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
6
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia • Tampa, Florida + 3 more
Completed Not applicable Interventional Results available

BMAC & Allograft vs BMP-2

NCT02924571
Conditions
Spinal Fusion
Interventions
Bone Marrow Aspirate Concentrate (BMAC) + Allograft, Recombinant Human Bone Morphogenetic Protein-2 (BMP), Autograft
Device · Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
New York, New York
Terminated Phase 1Phase 2 Interventional Results available

Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma

NCT01658904
Conditions
Multiple Myeloma, Leukemia, Plasma Cell
Interventions
Carfilzomib, Melphalan, Filgrastim
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Systemic Lupus Erythematosus
Interventions
Leukapheresis, Non-myeloablative high dose immunosuppressive therapy conditioning (HDIT), Autologous CD34+HPC transplantation (HSCT), Plasmapheresis, Rabbit anti-thymocyte globulin, Methylprednisolone, Growth colony stimulating factor (G-CSF), Corticosteroids, Mycophenolate mofetil, Azathioprine, Intravenous immunoglobulin, Methotrexate, Rituximab, Leflunomide
Procedure · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
5
States / cities
La Jolla, California • Los Angeles, California • Chicago, Illinois + 2 more
Completed Phase 1Phase 2 Interventional Results available

Lenalidomide and High-Dose Melphalan

NCT01079936
Conditions
Myeloma, Stem Cell Transplantation
Interventions
Lenalidomide, Melphalan, Stem Cell Infusion
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Houston, Texas
Conditions
Anterior Cruciate Ligament Reconstruction Rehabilitation
Interventions
Rehabilitation with Exercise and Psychological Support (REPS)
Behavioral
Lead sponsor
HealthPartners Institute
Other
Eligibility
15 Years to 21 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Bloomington, Minnesota
Terminated Not applicable Interventional

In Vitro Follicle Activation

NCT02496598
Conditions
Primary Ovarian Insufficiency, Infertility
Interventions
In Vitro Follicle Activation (IVA), Follicle Activation
Procedure · Drug
Lead sponsor
National Foundation for Fertility Research
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Lone Tree, Colorado
Conditions
Chronic Pancreatitis
Interventions
Prolastin-C, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Charleston, South Carolina
Recruiting Not applicable Interventional Accepts healthy volunteers

Star Matrix vs Autogenous Graft for Gingival Augmentation: Split-Mouth RCT

NCT07440303
Conditions
Lack of Keratinized Gingiva, Mucogingival Deformity - Insufficient Keratinized Tissue
Interventions
Starmatrix collagen membrane, Autogenous gingival graft
Device · Other
Lead sponsor
Harvard Medical School (HMS and HSDM)
Other
Eligibility
20 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Follicular Lymphoma
Interventions
Combination of treatment modalities
Other
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
St Louis, Missouri